12 April 2021: Clinical Research
Prostate Adenocarcinoma with Brain Metastasis: A Surveillance, Epidemiology, and End Results Database Analysis 2010–2015
Zin W. Myint ABCDEF* , Ayman H. Qasrawi ABCDEFDOI: 10.12659/MSM.930064
Med Sci Monit 2021; 27:e930064
Table 3 Cox regression analysis of association between prostate brain metastasis and other variables.
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | |
| Age (≤75 vs >75 years) | 0.72 (0.50–1.03) | 0.77 (0.53–1.1) | 0.16 | |
| Surgery (yes vs no) | 0.62 (0.39–0.99) | 0.68 (0.42–1.09) | 0.11 | |
| Chemotherapy (yes vs no) | 0.56 (0.32–0.98) | 0.60 (0.34–1.05) | 0.07 | |
| Race (white vs other) | 1.06 (0.71–1.58) | 0.8 | ||
| Lung metastasis (yes vs no) | 0.71 (0.47–1.07) | 0.1 | ||
| Bone metastasis (yes vs no) | 1.23 (0.74–2.05) | 0.43 | ||
| Liver metastasis (yes vs no) | 0.91 (0.54–1.55) | 0.7 | ||
| Grade group (I/II vs III/IV) | 0.59 (0.23–1.49) | 0.26 | ||